Clinical Trials Browser

Approved for marketing × ibrutinib × Clear all

NCT01833039 2025-02-03

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Approved for marketing

Recurrence, Lymphoma, Mantle-Cell

NCT02437019 2017-03-20

Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Approved for marketing

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell